Any current/future new fundraising through debt or equity?

The transcript does not explicitly mention any current or planned new fundraising through debt or equity. There is a focus on disciplined execution, cost management, and organic growth to fund expansions. Management highlights strong cash flows and cost-cutting initiatives (INR 120 crore planned savings) to support growth and margin improvement. Investments are being made in hospital expansions, digital platforms, and insurance businesses, but these appear funded through internal accruals and existing resources. No explicit mention of raising capital via debt or equity in the near term during

Any current/future capex/capital investment/strategic investment?

Six new hospitals are planned to be added between FY26 and FY27, with Pune and Defense Colony hospitals already soft commissioned in Q3 FY26. Sarjapur Bangalore and Calcutta hospitals are expected to start in Q4 FY26. Hyderabad and Gurugram hospitals anticipated around Q1 FY27 with enhanced facilities including comprehensive oncology programs. Brownfield expansions underway at Jubilee Hills and Secunderabad. Investment in new technologies and clinical programs, including AI interventions in oncology, radiology, and stroke care. Continued expansion of Apollo 24/7 digital platform and related ca

Future growth expectations in sales/revenue/volumes?

Healthcare Services revenue is expected to grow at 13% organically in existing beds over the next 2-3 years, with an additional 5% growth anticipated from new bed additions in the next two years. (Page 13) Apollo HealthCo's revenues grew 18% YoY, supported by an 18% growth in AHLL, indicating strong growth momentum. (Page 3) Digital business GMV (Gross Merchandise Value) growth is targeted between 25%-30% overall, with pharmacy business growing at ~30% YoY and quarter-on-quarter growth of around 5%-7%. Insurance and diagnostics businesses are also set to pick up from Q4 onwards. (Page 6) Ne

Future growth expectations in earnings/operating earnings/profits/EPS?

Base hospital network margins were around INR 10-15 crore costs built into Q2 FY26, equating to roughly 50 basis points of revenue, with margins already above 25% excluding new beds. The company expects existing hospital EBITDA margins to expand by up to 500 basis points over the next one to two years, targeting margins above 25%. The established hospitals reported 24.6% EBITDA margin in Q2 FY26, with an internal target to increase it further. Overall EBITDA losses from new hospitals are expected up to INR 150 crore for FY27 but these are expected to breakeven within 12 months of commissioning

IN US

Sale is live|00:00:00left today

Apollo Hospitals Enterprise LtdQ3 FY25Healthcare Services

Apollo Hospitals Enterprise Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹8,592P/E: 64.0Market Cap: ₹1.2L CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Healthcare Services revenue is expected to grow at 13% organically in existing beds over the next 2-3 years, with an additional 5% growth anticipated from new bed additions in the next two years. (Page 13)
→Apollo HealthCo's revenues grew 18% YoY, supported by an 18% growth in AHLL, indicating strong growth momentum. (Page 3)
→Digital business GMV (Gross Merchandise Value) growth is targeted between 25%-30% overall, with pharmacy business growing at ~30% YoY and quarter-on-quarter growth of around 5%-7%. Insurance and diagnostics businesses are also set to pick up from Q4 onwards. (Page 6)
→New hospitals additions: Six new hospitals are planned with phased commissioning from Q3 FY26 to Q1 FY27, expected to contribute to revenue growth. (Page 3)
→Improvements in case mix and patient complexity are driving average revenue per patient growth rather than tariff increases. (Page 14)
→Occupancy is targeted to improve to around 70%, supporting volume growth. (Page 11)

Margin guidance

Category 3

→Base hospital network margins were around INR 10-15 crore costs built into Q2 FY26, equating to roughly 50 basis points of revenue, with margins already above 25% excluding new beds.
→The company expects existing hospital EBITDA margins to expand by up to 500 basis points over the next one to two years, targeting margins above 25%.
→The established hospitals reported 24.6% EBITDA margin in Q2 FY26, with an internal target to increase it further.
→Overall EBITDA losses from new hospitals are expected up to INR 150 crore for FY27 but these are expected to breakeven within 12 months of commissioning.
→Cost-cutting measures targeting INR 120 crore reduction, with INR 60 crore achieved, are supporting margin expansion.
→Digital and AI initiatives are expected to drive operational efficiencies and improve profitability.
→Hospital organic growth expected to return to ~30%, aided by market expansions and recovery in international patient flows.

3 more insights locked — sign up free to unlock

Fundraise plans

→The transcript does not explicitly mention any current or planned new fundraising through debt or equity.
→There is a focus on disciplined execution, cost management, and organic growth to fund expansions.
→Management highlights strong cash flows and cost-cutting initiatives (INR 120 crore planned savings) to support growth and margin improvement.
→Investments are being made in hospital expansions, digital platforms, and insurance businesses, but these appear funded through internal accruals and existing resources.
→No explicit mention of raising capital via debt or equity in the near term during the Q2 FY26 earnings call.

Order book

The transcript does not explicitly mention current or expected orderbook or pending orders for Apollo Hospitals (AHEL). However, related capacity expansion and hospital commissioning plans were discussed: - Six new hospitals are planned for commissioning across FY26 and FY27, staggered across Q3, Q4, and Q1. - Soft commissioning of Defense Colony Cancer Hospital and Pune hospital started in Q3. - Sarjapur Bangalore and Calcutta hospitals are expected to start in Q4. - Hyderabad and Gurugram hospitals planned by early Q1 with expanded oncology and private room facilities. - Brownfield projects for Jubilee Hills and Secunderabad are underway. - The focus is on organic growth including 13% growth in Healthcare Services from existing beds plus 5% additional growth from new bed additions over the next 2 years. No direct reference to orderbook or pending orders was provided in the available transcript pages.

Capex plans

Yes

→Six new hospitals are planned to be added between FY26 and FY27, with Pune and Defense Colony hospitals already soft commissioned in Q3 FY26.
→Sarjapur Bangalore and Calcutta hospitals are expected to start in Q4 FY26.
→Hyderabad and Gurugram hospitals anticipated around Q1 FY27 with enhanced facilities including comprehensive oncology programs.
→Brownfield expansions underway at Jubilee Hills and Secunderabad.
→Investment in new technologies and clinical programs, including AI interventions in oncology, radiology, and stroke care.
→Continued expansion of Apollo 24/7 digital platform and related capabilities.
→Hiring planned ahead of hospital openings (e.g., Pune, Gurgaon) with some ramp-up costs captured in Q2 FY26.
→Focus on improving existing hospital utilization and EBITDA margins while managing losses from new hospitals capped at INR 150 crore for FY27.

How does Apollo Hospitals Enterprise Ltd rank vs peers in Healthcare Services?

Pro feature

1Apollo Hospitals Enterprise Ltd

Rev 3Mar 3

See full Healthcare Services sector rankings

Want more stocks like Apollo Hospitals Enterprise Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio